Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash & Current Investments (2016 - 2025)

Lexaria Bioscience's Cash & Current Investments history spans 11 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 45.5% year-over-year to $4.4 million; the TTM value through Nov 2025 reached $4.4 million, down 45.5%, while the annual FY2025 figure was $1.8 million, 72.17% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $4.4 million at Lexaria Bioscience, up from $1.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $11.8 million in Q3 2021 and bottomed at $1.5 million in Q3 2023.
  • The 5-year median for Cash & Current Investments is $6.4 million (2022), against an average of $6.2 million.
  • The largest annual shift saw Cash & Current Investments skyrocketed 1688.12% in 2021 before it tumbled 76.01% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $10.2 million in 2021, then crashed by 52.8% to $4.8 million in 2022, then tumbled by 57.8% to $2.0 million in 2023, then surged by 300.58% to $8.1 million in 2024, then tumbled by 45.5% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Cash & Current Investments are $4.4 million (Q4 2025), $1.8 million (Q3 2025), and $4.6 million (Q2 2025).